Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata available, this FDA Warning Letter was issued to Abington Memorial Hospital's Institutional Review Board (IRC) on June 24, 2019, regarding biologics products. While the specific violations cannot be determined without access to the full letter text, the warning likely concerns compliance issues related to the review or oversight of biologic product research or clinical activities under the IRB's jurisdiction. The letter falls under FDA's biologics regulatory authority, though the specific issuing office is not identified in the available metadata.